Date | Insider | Price | Amount |
---|---|---|---|
3-4-2024 Insider Buy |
Alex Sapir See Remarks |
$11.35 CAGR » |
$492,027.60 43,360 shares |
1-20-2023 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$13.00 CAGR » |
$24,999,988.00 1,923,076 shares |
1-4-2023 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$7.28 CAGR » |
$1,314,805.84 180,703 shares |
12-19-2022 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$5.90 CAGR » |
$582,813.66 98,787 shares |
12-16-2022 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$5.44 CAGR » |
$13,073,873.90 2,403,049 shares |
12-27-2022 Insider Buy |
RA CAPITAL MANAGEMENT, L.P. >10% Owner |
$5.99 CAGR » |
$24,509.87 4,089 shares |
6-28-2021 Insider Buy |
Christopher Morabito Chief Medical Officer |
$9.16 CAGR » |
$10,076.00 1,100 shares |
6-28-2021 Insider Buy |
Curtis Gale Oltmans SVP, General Counsel |
$9.01 CAGR » |
$9,802.88 1,088 shares |
6-28-2021 Insider Buy |
Peter G. Thomson VP Finance & Accounting |
$9.00 CAGR » |
$20,700.00 2,300 shares |
6-28-2021 Insider Buy |
James A. Geraghty Director |
$9.16 CAGR » |
$91,600.00 10,000 shares |
7-22-2019 Insider Buy |
Sanofi >10% Owner |
$16.00 CAGR » |
$1,500,000.00 93,750 shares |
7-22-2019 Insider Buy |
Mark J. Levin Director and >10% Owner |
$16.00 CAGR » |
$1,300,000.00 81,250 shares |
7-22-2019 Insider Buy |
Casdin Capital, LLC >10% Owner |
$15.84 CAGR » |
$2,217,495.00 140,000 shares |
7-22-2019 Insider Buy |
6 Dimensions Capital, L.P. >10% Owner |
$16.00 CAGR » |
$1,900,000.00 118,750 shares |
7-22-2019 Insider Buy |
Third Rock Ventures III, L.P. >10% Owner |
$16.00 CAGR » |
$1,300,000.00 81,250 shares |
7-22-2019 Insider Buy |
Third Rock Ventures IV, L.P. >10% Owner |
$16.00 CAGR » |
$1,300,000.00 81,250 shares |
Also See: Institutional Holders of FULC
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 03/05/2024 | |
End date: | 05/01/2024 | |
Start price/share: | $10.96 | |
End price/share: | $7.33 | |
Dividends collected/share: | $0.00 | |
Total return: | -33.12% | |
Annualized Gain: | -215.87% | |
Starting investment: | $10,000.00 | |
Ending investment: | $6,688.00 | |
Years: | 0.15 |
Fulcrum Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Fulcrum Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding FULC
Free FULC Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Other companies seeing insider buying close in time to when the Fulcrum Therapeutics Insider Buying occurred are:
Universal Technical Institute Insider Buying |